Comparative bioethics in bipolar and epilepsy research

Seizure

Volumn 11, Issue 1, 2002, Pages 51-56

  Kaufman, Kenneth R ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Antiepileptic drugs; Bipolar disorders; Epilepsy; Ethics; Psychotropics; Research; Suicide; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; LITHIUM; NEW DRUG; OXCARBAZEPINE; PLACEBO; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VIGABATRIN; ZONISAMIDE;

ADD ON THERAPY; ARTICLE; BIPOLAR DEPRESSION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; EPILEPSY; FOOD AND DRUG ADMINISTRATION; HOSPITAL PATIENT; HUMAN; INFORMED CONSENT; KINDLING; MAJOR CLINICAL STUDY; MANIC DEPRESSIVE PSYCHOSIS; MEDICAL ETHICS; MEDICAL LITERATURE; MEDICAL RESEARCH; MENTAL DETERIORATION; META ANALYSIS; METHODOLOGY; MONOTHERAPY; MORBIDITY; POPULATION RESEARCH; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PSYCHIATRY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEIZURE; STATISTICAL ANALYSIS; SUICIDE;

EID: 0036185223     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1053/seiz.2001.0585     Document Type: Article

References (59)

1. Hippocrates. The oath
2. Three-year outcomes for maintenance therapies in recurrent depression
3. The use of placebo control groups in the assessment of psychiatric drugs: An historical context
4. An NIMH perspective on the use of placebos
5. Placebo response in depression: A search for predictors
6. The placebo problem remains
7. Declaration of Helsinki
8. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the Food and Drug Administration database
9. Special issues in trial design and use of placebo in bipolar illness
10. Bipolar II disorders and comorbidity
11. Suicide and bipolar disorder
12. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders
13. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders
14. Efficacy of lithium in mania and maintenance therapy of bipolar disorder
15. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders
16. Placebo effect in randomized, controlled studies of acute bipolar mania and depression
17. Efficacy of divalproex vs lithium and placebo in the treatment of mania
18. Valproate in the treatment of acute mania. A placebo-controlled study
19. Olanzapine versus placebo in the treatment of acute mania
20. Efficacy of olanzapine in acute bipolar mania
21. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression
22. Placebo effect in randomized, controlled maintenance studies of patients with bipolar disorders
23. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder
24. Challenging our past paradigm in the management of epilepsy
25. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: A double-blind, placebo-controlled study
26. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures
27. Tiagabine for complex partial seizures: A randomized, add-on, dose-response trial
28. Topiramate as add-on therapy: Pooled analysis of randomized controlled trials in adults
29. Zonisamide add-on for drug-resistant partial epilepsy
30. New antiepileptic drugs: Comparison of key clinical trials
31. Vigabatrin as add-on therapy for adult complex partial seizures: A double-blind, placebo-controlled multicentre study
32. Adjunctive therapy with oxcarbazepine in children with partial seizures
33. Multicenter double-blind, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures
34. Felbamate in the treatment of Lennox-Gastaut syndrome: Results of a 12-month open-label study following a randomized clinical trial
35. The new antiepileptic drugs: A systematic review of their efficacy and tolerability
36. Monotherapy clinical trials of new anti-convulsants: Design, indications, and controversies
37. Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations
38. Adjustment of carbamazepine dose to offset the effects of the interaction with remacemide hydrochloride in a double-blind, multicentre, add-on drug trial (CR2237) in refractory epilepsy
39. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy
40. Felbamate monotherapy for partial-onset seizures: An active control trial
41. An active-control trial of lamotrigine monotherapy for partial seizures
42. Clinical development outlook of oxcarbazepine
43. Felbamate monotherapy: Implications for antiepileptic drug development
44. Oxcarbazepine: Double-blind, randomized, placebo-control, monotherapy trial for partial seizures
45. Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design
46. Innovative designs of controlled trials in epilepsy
47. Evaluation of antiepileptic drug efficacy. A review of clinical trial design
48. Monotherapy trials with the new antiepileptic drugs: Study designs, practical relevance and ethical implications
49. Design issues for the clinical evaluation of psychotropics drugs
50. Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder
51. Life charting of affective disorders
52. The Stanley Foundation Bipolar Treatment Outcome Network: I. Longitudinal methodology
53. Demographics and illness characteristics of the first 261 patients
54. Lamotrigine for the treatment of bipolar disorders: A clinical case series
55. Open-label adjunctive topiramate in the treatment of bipolar disorders
56. What makes clinical research ethical?
57. Ethics in adherence promotion and monitoring